1 Longitudinal serologic and viral testing post–SARS-CoV-2 infection and post-receipt of mRNA COVID-

2 **19** vaccine in a nursing home cohort—Georgia, October 2020–April 2021

- 3 Farrell A. Tobolowsky, DO, MS^{1*}, Michelle A. Waltenburg, DVM, MPH^{1*}, Erin D. Moritz, PhD¹, Melia
- 4 Haile, MPH, CHES¹, Juliana C. DaSilva, MA¹, Amy J. Schuh, PhD, MPH¹, Natalie J. Thornburg, PhD¹,
- 5 Adrianna Westbrook, MPH¹, Susannah L. McKay, PhD¹, Stephen P. LaVoie, PhD¹, Jennifer M. Folster,
- 6 PhD¹, Jennifer L. Harcourt, PhD¹, Azaibi Tamin¹, Megan M. Stumpf¹, Lisa Mills¹, Brandi Freeman, PhD,
- 7 MPH¹, Sandra Lester, PhD¹, Elizabeth Beshearse, PhD¹, Kristin D. Lecy, RN, MPH¹, Laura G. Brown, PhD¹,
- 8 Geroncio Fajardo¹, Jeanne Negley, MBA², L. Clifford McDonald, MD¹, Preeta K. Kutty, MD, MPH¹, and
- 9 Allison C. Brown, PhD¹; for the CDC Infection Prevention and Control Team
- 10 *Both authors contributed equally to this work.

11 Author Affiliations:

- ¹Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA, 30333
- ²Georgia Department of Public Health, 2 Peachtree Street, Atlanta, GA, 30303

14 **Corresponding Author:**

- 15 Farrell A. Tobolowsky, DO, MS
- 16 Centers for Disease Control and Prevention
- 17 1600 Clifton Road
- 18 Atlanta, GA, USA 30329
- 19 Phone: 404-718-3635
- 20 Email: oqk3@cdc.gov
- 21 The findings and conclusions in this report are those of the authors and do not necessarily represent the
- 22 official position of the Centers for Disease Control and Prevention.
- 23 Use of trade names and commercial sources is for identification only and does not imply endorsement
- 24 by the U.S. Department of Health and Human Services.

25 Abstract:

- 26 Importance: There are limited data describing SARS-CoV-2–specific immune responses and their
- 27 durability following infection and vaccination in nursing home residents.
- 28 Objective: To evaluate the quantitative titers and durability of binding antibodies detected after SARS-
- 29 CoV-2 infection and subsequent COVID-19 vaccination.
- 30 Design: A prospective longitudinal evaluation included nine visits over 150 days; visits included
- 31 questionnaire administration, blood collection for serology, and paired anterior nasal specimen
- 32 collection for testing by BinaxNOW[™] COVID-19 Ag Card (BinaxNOW), reverse transcription polymerase
- 33 chain reaction (RT-PCR), and viral culture.
- 34 Setting: A nursing home during and after a SARS-CoV-2 outbreak.
- 35 Participants: 11 consenting SARS-CoV-2–positive nursing home residents.
- 36 Main Outcomes and Measures: SARS-CoV-2 testing (BinaxNOW[™], RT-PCR, viral culture); quantitative
- 37 titers of binding SARS-CoV-2 antibodies post-infection and post-vaccination (beginning after the first
- 38 dose of the primary series).
- 39 Results: Of 10 participants with post-infection serology results, 9 (90%) had detectable Pan-Ig, IgG, and
- 40 IgA antibodies and 8 (80%) had detectable IgM antibodies. At first antibody detection post-infection,
- 41 two-thirds (6/9, 67%) of participants were RT-PCR–positive but none were culture positive. Ten
- 42 participants received vaccination; all had detectable Pan-Ig, IgG, and IgA antibodies through their final
- 43 observation ≤90 days post-first dose. Post-vaccination geometric means of IgG titers were 10–200-fold

44 higher than post-infection.

45 Conclusions and Relevance: Nursing home residents in this cohort mounted robust immune responses
46 to SARS-CoV-2 post-infection and post-vaccination. The augmented antibody responses post-vaccination

- 47 are potential indicators of enhanced protection that vaccination may confer on previously infected
- 48 nursing home residents.

49 Introduction

50 COVID-19 outbreaks in nursing homes have caused significant morbidity and mortality, including 51 740,034 cases and 141,084 deaths in residents as of December 5, 2021 (1). Although nursing home 52 residents are typically older with multiple comorbidities compared with the general population, 53 preliminary data show they frequently mount an immune response within 15 to 30 days of SARS-CoV-2 54 diagnosis (2, 3). However, the kinetics of SARS-CoV-2-specific binding antibody titers and isotypes that 55 persist beyond the early acute phase of infection are unknown. 56 Vaccination is a key strategy to prevent COVID-19 morbidity and mortality in nursing home 57 residents (4). Residents were prioritized for early COVID-19 vaccination because nursing homes 58 experienced rapid transmission and severe disease outcomes. mRNA vaccines were the first available, 59 and early post-emergency use authorization data demonstrated that the administration of mRNA 60 vaccines led to a decrease in new SARS-CoV-2 infections in nursing home residents (5-7). However, in 61 some instances, especially in the context of emerging SARS-CoV-2 variants, vaccinated residents have 62 tested positive for SARS-CoV-2 and developed COVID-19 during routine screening and outbreaks (8, 9). 63 Despite these infections in vaccinated persons, studies indicate that overall, mRNA vaccines have 64 decreased COVID-19 morbidity and mortality in nursing home residents (10, 11). 65 Characterizing SARS-CoV-2-specific immune responses elicited through natural infection or

vaccination, and their durability in nursing home residents, is critical to understanding potential immune protection against infection. While preliminary data show that nursing home residents mount initial immune responses to infection and vaccination, the duration and strength of this immune response remains unknown. Additionally, information on how antibody development relates to viral RNA detection and virus shedding in nursing home residents is limited. In a longitudinal evaluation of SARS-CoV-2–positive nursing home residents, we describe (a) how the clinical course of COVID-19 illness,

72	severity of illness, and underlying medical conditions related to antibody development, (b) how
73	repeated viral testing results correlated with antibody development post-diagnosis, and (c) the
74	comparative titers and durability of immunoglobulin isotypes (i.e., Pan Ig, IgG, IgA, IgM) mounted in
75	response to SARS-CoV-2 infection and receipt of the Pfizer-BioNTech COVID-19 Vaccine.
76	Methods
77	A longitudinal evaluation to characterize SARS-CoV-2–specific immune responses was initiated
78	in a 149-bed nursing home that began experiencing an outbreak of SARS-CoV-2 infections in October
79	2020. Residents were eligible to participate if they were medically stable, had decision-making capacity,
80	and provided informed consent after testing SARS-CoV-2–positive using BinaxNOW™ COVID-19 Ag Cards
81	(BinaxNOW) (Abbott; Scarborough, ME) in any of three rounds of Centers for Disease Control and
82	Prevention (CDC)-led facility-wide point prevalence surveys (PPS) or by previous testing results
83	generated by the facility (12, 13). The first facility-generated positive viral test occurred in early October
84	2020. CDC PPS occurred during late October to early November 2020 and the longitudinal evaluation
85	included visits from October 25, 2020 through April 1, 2021.
86	Upon enrollment, the first four visits were conducted every other day. During these visits, CDC
87	administered a standardized questionnaire to each participant, blood specimens were collected for
88	serology, and paired bilateral anterior nasal specimens were collected for testing by BinaxNOW and real-
89	time reverse transcription polymerase chain reaction (RT-PCR) (14). Participants were interviewed to
90	obtain demographics and information about their COVID-19 exposures, signs, symptoms, and
91	hospitalization. After the first four visits, follow-up visits occurred monthly for a total of nine visits
92	(Figure 1). During these monthly follow-up visits, one nasal specimen was collected for RT-PCR, blood
93	specimens were collected for serology, and participants were interviewed about COVID-19 signs,
94	symptoms, and hospitalizations since the previous visit.

95 The facility began administering the primary series of mRNA COVID-19 vaccines during the 96 evaluation period (4); willing participants were vaccinated between January–February 2021. Timing of 97 vaccination was determined by the facility and timing of receipt of the first vaccine dose varied by 98 participant. CDC visits 6–9 occurred after facility vaccine clinics were initiated. In this evaluation, 99 participants were considered fully vaccinated two weeks after receiving the second dose of the mRNA 100 COVID-19 vaccine.

Electronic medical chart abstraction was performed to obtain supplemental information on participants' past medical history, medications, laboratory test results, clinical outcomes, and vaccine administration. Information from questionnaires and chart abstraction were entered into a Research Electronic Data Capture (REDCap) database (15, 16). If visits occurred while a participant was hospitalized, specimens and clinical data were not collected from that participant; however, that participant could choose to continue in the evaluation upon return to the nursing home.

107 Reported COVID-19 symptom status was characterized as asymptomatic or symptomatic, and 108 participants' illnesses were further characterized as mild, moderate, or severe. A participant was 109 asymptomatic if he or she did not report any COVID-19 signs or symptoms in the 14 days before testing 110 positive or during the evaluation period. Mild illness included participants with asymptomatic COVID-19 111 infections and those who reported COVID-19 signs or symptoms without dyspnea or evidence of lower 112 respiratory tract involvement. Moderate illness included participants with signs of lower respiratory 113 disease by clinical assessment or imaging, and severe disease included participants with tachypnea (>30 114 breaths per minute), oxygen saturation <90% (or decrease from baseline over 3% for at least two 115 consecutive values), hospitalization, or death (17). An immunocompromised condition included the 116 following: recent or active malignancy, bone marrow transplant, solid organ transplant, primary or 117 secondary immune deficiency, or the use of oral or intravenous steroids or any immunosuppressant 118 drugs.

119	Details of specimen collection, BinaxNOW, RT-PCR, and viral culture methods have been
120	described previously (12). Viral culture was conducted on RT-PCR-positive specimens with a cycle
121	threshold (Ct) value <35. Serum specimens were tested for anti–SARS-CoV-2 antibodies using an
122	enzyme-linked immunosorbent assay targeting the extracellular domain of the SARS-CoV-2 spike protein
123	(18). This assay uses anti-pan-immunoglobulin (Ig) secondary antibodies that detect any SARS-CoV-2
124	immunoglobulin isotype, including IgG, IgM, and IgA. Seroconversion was defined as a signal to
125	threshold >1 at a serum dilution of 1:100 for any isotype; seroreversion occurred when a previously
126	seropositive participant became seronegative.
127	Day 0 for each participant was defined as the day of their first SARS-CoV-2-positive test
128	(BinaxNOW or RT-PCR) by either the facility or CDC PPS. We defined the entire evaluation period as
129	"post-diagnosis", the time period after each participant's SARS-CoV-2 diagnosis and before vaccination
130	as "post-infection," and the time period after a participant received their first vaccine dose of the
131	primary series as "post-vaccination" (Figure 1).
132	Geometric means of serum antibody titers were calculated among all participants with
133	specimens collected during specific post-infection and post-vaccination time periods: 0–14, 15–30, 31–
134	60, and 61–90 days. Ratios for mean titers post-vaccination to mean titers post-infection were
135	calculated for each isotype; only antibody titers >100 were included in these ratios. Median serum
136	antibody titers and ratios of median titers post-vaccination to post-infection were also calculated. Data
137	were analyzed by Microsoft Excel (Microsoft Office 365 Version; Redmond, WA) and SAS, version 9.4
138	(SAS Institute; Cary, NC).
139	This evaluation was reviewed by the National Center for Emerging and Zoonotic Infectious
140	Diseases Human Studies Coordinator at the CDC and was determined to be non-research public health

surveillance as defined in 45 CF 46.102 (19-23). It was determined that ethical review by the CDC Human

142 Research Protection Office and IRB review was not required. This work did not receive any non-CDC

- 143 funding support.
- 144 Results
- 145 Demographic and clinical characteristics

146 Among 127 residents who participated in at least one CDC PPS, 47 (37%) antigen-positive 147 residents were identified; 31 (66%) antigen-positive residents were eligible for enrollment in this 148 longitudinal evaluation, of which 12 (39%) agreed to participate. Eight (67%) participants tested positive 149 by facility testing conducted prior to CDC PPS. One participant died before the second follow-up visit and 150 was excluded from analysis. The median age of the remaining 11 participants was 74 years (range: 37– 151 90 years) and seven (64%) were male (Table 1). Seven (64%) participants were White and four (36%) 152 were Black; no participants reported Hispanic ethnicity. The most common underlying conditions were 153 cardiovascular disease (11, 100%) and diabetes (6, 55%); 10 (91%) participants had \geq 3 underlying 154 conditions (Table 1). One participant (A) was immunocompromised with B-cell lymphoma. Four (36%) 155 participants (C, D, G, H) were classified as having severe COVID-19 illness, all of whom required 156 hospitalization; one (D) died during follow-up after visit 8. Two (18%) participants (E, J) were 157 asymptomatic. Ten of 11 (91%) participants received two doses of the Pfizer-BioNTech COVID-19 158 Vaccine during the evaluation period; the other participant (C) refused the vaccine. 159 Laboratory results

A total of 166 anterior nasal specimens (53 paired for RT-PCR and BinaxNOW; 60 unpaired for RT-PCR only) and 61 blood specimens were analyzed. Participants had a median of 6 (interquartile range [IQR]: 5–7) blood specimens collected across a median of 141 days (IQR: 141–163). One participant (G) did not provide blood specimens during the post-infection period but did during the post-vaccination

164 period. All blood specimens from participant C were considered post-infection due to vaccination

165 refusal.

166 Antibody profile post-infection and prior to vaccination

Of 10 participants with post-infection serology results, 9 (90%) had detectable Pan-Ig, IgG, and IgA antibodies, 8 (80%) had detectable IgM antibodies, and one participant (I) did not mount any binding antibodies post-infection. Among the seven participants with serology conducted within 30 days postinfection, the median time to detection was 13 days for Pan-Ig and IgG (IQR: 11–17); 16 days for IgA (IQR: 12–17). Six (86%) of these participants with IgM antibodies had a median time to detection of 15 days (IQR: 12–17).

At the time of first antibody detection post-infection, two-thirds (6/9, 67%) of participants were still RT-PCR–positive but none were viral culture positive (Appendix Figure 1). The median Ct value at the time of first antibody detection for these participants was 29 (IQR: 25–34). Participant G did not have blood specimens collected post-infection and participant I did not have detectable antibodies postinfection, but both were RT-PCR–negative and had prior negative viral culture results at the time of first antibody detection. Antibody detection was either concurrent with or subsequent to negative viral culture results but did not correlate with negative RT-PCR or BinaxNOW results (Appendix Figure 1).

Pan-Ig and IgG rose and remained elevated post-infection (Figure 2). IgM and IgA titers started to decline during the 31–60 days post-infection; seroreversion in these isotypes occurred in some participants (J, K, L) by 50 days post-infection and before vaccination (Appendix Figure 2). The participant (C) who declined vaccination had detectable Pan-Ig, IgG, and IgA antibodies for at least 150 days post-diagnosis (Appendix Figure 3). Participant H had lower post-infection antibody titers overall and had lymphopenia as determined in a blood specimen collected within 30 days prior to enrollment.

186 Antibody profile post-vaccination

187	Among the 10 participants vaccinated during the evaluation period, timing of the first vaccine
188	dose varied by participant and occurred between 71–105 days post-diagnosis. All 10 (100%) had
189	detectable Pan-Ig, IgG, and IgA antibodies and six (60%) had detectable IgM antibodies post-vaccination
190	(Appendix Figure 2). Pan-Ig, IgG, and IgA titers began to decrease during 61–90 days post-vaccination
191	(141 days post-diagnosis) (Figure 2).
192	Post-infection geometric means were highest during 15–30 days for IgA, 31–60 days for IgM and
193	IgG, and 61–90 days for Pan-Ig (Table 2). Post-vaccination geometric means were highest during 0–14
194	days for IgM, 15–30 days for Pan-Ig, and 61–90 days for IgG and IgA (Table 2). Participants demonstrated
195	higher Pan-Ig, IgG, and IgA titers post-second vaccine dose than pre-first dose. The largest geometric
196	mean titer ratios were measured during specific post-vaccination and post-infection time periods: 15–30
197	days for Pan-Ig (142.3) and 31–60 days for IgG (200.5) and IgA (4.4). Geometric mean IgM titer ratios
198	were not calculated during 61–90 days because all post-vaccination titers were below the limit of
199	detection. Median serum antibody titers and ratios during post-infection and post-vaccination time
200	periods are displayed in Appendix Table 1.
201	Participant J had a substantial increase in IgG titers post-vaccination; this participant received
202	their first vaccine dose on day 105 post-diagnosis, much later than most participants who received their
203	first vaccine dose earlier (Appendix Figure 3). Participant A who was immunocompromised with B-cell
204	lymphoma and classified as having mild to moderate COVID-19 disease had similar titers as other
205	participants. The unvaccinated participant (C) had lower Pan-Ig and IgG titers than vaccinated
206	participants after 90 days post-diagnosis (Appendix Figure 2).
207	Discussion:
200	

Although there have been concerns about immunosenescence causing an inadequate immune
 response to SARS-CoV-2 infection and vaccination in the nursing home population, anti–SARS-CoV-2

antibodies were consistently detected throughout the evaluation period in this nursing home cohort.

- 211 Furthermore, antibody responses in previously infected participants were augmented after vaccination
- and were still present throughout the evaluation period.
- 213 Some participants were antigen and RT-PCR positive at the time of first antibody detection; 214 however, no culturable virus was identified in respiratory specimens following detection of antibodies. 215 In general population studies, infected individuals may initially have positive nucleic acid amplification 216 tests (including RT-PCR) when anti–SARS-CoV-2 antibodies are first detected but are markedly less likely 217 to have positive results following antibody development (24). Specifically, detection of binding IgG 218 antibodies is associated with the absence of replication-competent virus (25). As a positive viral culture 219 is a likely indicator of the presence of replication-competent virus, our findings further support 220 seroconversion as a potential marker of non-infectivity post-infection and pre-vaccination (26). 221 Most participants developed all anti–SARS-CoV-2 antibody isotypes that were tested post-
- 222 infection, highlighting the diversity of antibody development in this nursing home cohort. The 223 participant who did not develop antibodies post-infection was only tested on Days 3 and 8. Pan-Ig and 224 IgG titers rose and remained elevated post-infection while IgM and IgA titers began to dissipate around 225 30 days post-infection. The duration of IgA positivity was longer than IgM. Similar kinetics have been 226 described in previous studies (27, 28). Prior reports have also suggested that higher titers are more 227 commonly associated with severe disease (29-31). In this cohort, guantitative antibody development did 228 not differ between those with mild to moderate and severe illness; however, our small sample size may 229 have limited our ability to detect a meaningful difference.

Prior studies reported that post-infection antibodies can be detected for at least six months
after diagnosis in the general population (32) and in nursing home cohorts (33). In this assessment, one
unvaccinated participant (C) had Pan-Ig, IgG, and IgA antibodies detected at 150 days (five months) post-

infection when our evaluation period ended, which may indicate antibody durability even in the absence
of vaccination. While our findings add to the growing body of evidence that nursing home residents can
maintain detectable binding antibodies for at least five months after diagnosis of SARS-CoV-2 infection,
we were unable to determine the maximum duration of post-infection antibodies because most
participants in our cohort were vaccinated 71–105 days post-diagnosis.

238 This analysis highlights the augmented impact of COVID-19 vaccination on post-infection 239 antibody titers, and likely enhanced immune protection, in previously infected nursing home residents 240 (34, 35). Evaluating titers of specific binding isotypes, participants had more robust Pan-Ig, IgG, and IgA 241 titers post-vaccination. Post-vaccination geometric mean titers of IgG were 10–200-fold higher than 242 post-infection, which is consistent with reported post-vaccination titer increases in healthcare workers 243 who had previous SARS-CoV-2 infection (36, 37). While more information is needed to understand the 244 correlation of post-mRNA vaccination titers with immune protection, a study by Feng et al. among 245 recipients of the ChAdOx1 nCoV-19 vaccine demonstrated a correlation between binding IgG antibody 246 titers and vaccine efficacy (38). Moreover, Feng et al. were able to derive threshold antibody levels that 247 correlated with differing levels of vaccine efficacy against symptomatic SARS-CoV-2 infection (38). 248 Applying these criteria to our nursing home cohort, all vaccinated participants surpassed the IgG titer 249 threshold that correlated with 80% vaccine efficacy two weeks after receiving their second vaccine dose. 250 Previous studies have shown increases in both IgG and IgA post-vaccination, with IgA detected

in both serum and mucosal sources (39-41). Robust IgG and IgA responses likely induce systemic and mucosal protection (42). IgA has been found to dominate the early neutralizing antibody response to SARS-CoV-2; a similar IgA response after mRNA vaccination has been hypothesized (42). In this evaluation, post-vaccination geometric mean titers of IgA were 2–4-fold higher than post-infection titers, suggesting that IgA could be used as an indicator of mRNA vaccine response.

256 Our evaluation had several limitations. We had a small sample size, preventing statistical 257 comparisons and potentially limiting the generalizability of our findings. Participants enrolled in our 258 evaluation only received the Pfizer-BioNTech COVID-19 Vaccine; therefore, we were unable to describe 259 the impact of vaccination with other products. Some participants were unable to provide blood 260 specimens when requested and most visits occurred only monthly, so we likely missed the exact timing 261 of seroconversion, peak antibody titers, and seroreversion. Not detecting antibodies in one participant 262 during this first 30 days post-infection was possibly an artifact of timing our collections relative to their 263 infection. Descriptions of antibody duration were limited by the length of the evaluation period. Seven 264 participants had visits that occurred one day after their first vaccine; though these visits were 265 categorized as post-vaccination, we do not know if titers observed from this visit were a continuation of 266 responses primed by their previous infection or a result of the vaccine already augmenting that 267 response. Therefore, we may have underestimated the scale of post-vaccination augmentation because 268 those titer calculations were influenced by values from measurements that were likely more reflective 269 of the post-infection time period. Limited electronic medical record documentation of vital signs, 270 including oxygen saturation, and the difficulty of discerning COVID-19 symptomology in a nursing home 271 cohort with multiple underlying comorbidities, chronic symptoms, and a modified clinical presentation 272 of particular signs and symptoms made it challenging to classify severity of illness. Lastly, since this 273 evaluation occurred before the rise of the SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) 274 variants in the United States, we do not know how participants' post-infection and post-vaccination 275 antibody responses could differ in the setting of these and other emerging SARS-CoV-2 variants. 276 Conclusion

The duration and diversity of binding antibodies observed in this cohort of nursing home
 residents could have implications for durability of immunity to SARS-CoV-2. Our findings of augmented
 Pan-Ig, IgG, and IgA antibody responses post-vaccination in nursing home residents with recent infection

- 280 underscore the importance of vaccination efforts, especially where there is vaccine hesitancy among
- nursing home staff (43). While it is unknown how long these anti–SARS-CoV-2 antibodies persist
- following vaccination, findings from this evaluation suggest that nursing home residents do mount a
- robust humoral immune response to SARS-CoV-2 post-infection and post-vaccination.
- 284 Members of the CDC Infection Prevention and Control Team who contributed to this work but did not
- author it: Amelia Bhatnagar, BS; Jonathan Bryant-Genevier, PhD; Dustin W. Currie, PhD, MPH; Davina
- 286 Campbell, MS, MPH; Sarah E. Gilbert, MPH; Kelly M. Hatfield, MSPH; David A. Jackson, MD, MPH; John A.
- Jernigan, MD, MS; James L. Dawson, PhD; Matthew J. Hudson, MD, MPH; Kahaliah Joseph, MSc; Sujan C.
- 288 Reddy, MD, MSc; and Malania M. Wilson, MS, MBA.
- 289
- Acknowledgements: We are grateful to all residents and staff at the nursing home for their participation
- and support of this evaluation during an especially challenging time. We also thank the Georgia
- 292 Department of Public Health.

293 Table 1. Demographic and clinical characteristics of participants^{*} (N=11) in a nursing home cohort—

294 Georgia, October 2020–April 2021

Characteristic		Participants
Age, median [range] in years	74 [37-90]	
	n	%
Male	7	64
White	7	64
Black	4	36
Non-Hispanic/Latino	11	100
Underlying conditions [†]		
>3 underlying conditions	10	91
Cardiovascular disease	11	100
Hypertension	10	91
Coronary artery disease	6	55
Hyperlinidemia	3	27
Heart failure	3	27
Cerebrovascular accident	3	36
Diabetes mellitus	-	55
Chronic kidney disease	3	27
Chronic obstructive nulmonary disease	3	37
Neurologic disease	2	18
Cancer [‡]	2	18
Former/current smoker	10	91
Tomer/current shoke	10	91
Severity of illness [§]		
Mild to moderate disease	7	64
Severe disease	4	36
COVID-19 symptom status		
Symptomatic	9	82
Asymptomatic	2	18
Clinical outcome		
Lespitalized	4	26
	4	30
Died	1	9

295 ້	* Participants were identified amon	g the cohort of nursing	g home residents if the	y were medically stable,
-------	-------------------------------------	-------------------------	-------------------------	--------------------------

- 296 had decision-making capacity, and provided informed consent after testing SARS-CoV-2–positive using
- 297 BinaxNOW[™] COVID-19 Ag Cards in any of three rounds of facility-wide point prevalence surveys
- 298 conducted by Centers for Disease Control and Prevention staff during late October to early November
- 299 2020.
- ⁺ None of the participants had hepatic disease as an underlying condition.
- ^{*} One participant had unspecified B-cell lymphoma and one participant had a malignant neoplasm of
- 302 colon, per medical record review.
- [§] Mild illness was defined as having signs or symptoms without dyspnea or evidence of lower respiratory
- 304 tract involvement, moderate illness included signs of lower respiratory disease by clinical assessment or
- imaging, and severe disease was tachypnea (>30 breaths per minute), oxygen saturation < 90% (or
- 306 decrease from baseline over 3%), hospitalization, or death. Asymptomatic participants were considered
- 307 to have mild illness.
- 308 ^{||} Symptoms represent the earliest reported COVID-19 symptoms from 14 days prior to facility-wide CDC
- testing through the end of the evaluation period.

- 310 Table 2. Geometric means of anti–SARS-CoV-2 serum antibody titers and ratios post-vaccination and
- 311 post-infection by isotype among participants (N=11) in a nursing home cohort—Georgia, October

312 **2020–April 2021**^{*,†}

Time period	Post-in	fection	Post-vaccination		Ratio post-
(days)	No. specimens tested	Geometric mean	No. specimens tested	Geometric mean	vaccination to post-infection
Pan-Ig					
0–14	5	647.9	9	10181.0	15.7
15–30	7	2039.4	8	290111.6	142.3
31–60	9	4432.9	9	79175.1	17.9
61–90	3	4438.9	4	44136.9	9.9
lgG					
0–14	5	885.0	9	11879.3	13.4
15–30	7	4295.0	8	537275.5	125.1
31–60	9	10156.4	9	2036648.2	200.5
61–90	3	6789.3	4	105524.0	15.5
IgA					
0–14	4	198.9	3	397.6	2.0
15–30	7	442.2	8	1663.5	3.8
31–60	7	390.5	9	1734.4	4.4
61–90	2	419.3	4	672.2	1.6
lgM					
0–14	4	324.1	3	1026.2	3.2
15–30	5	536.9	2	400.5	0.7
31–60	5	702.2	3	525.1	0.7
61–90	2	260.0	0	_	_

313

^{*}The post-infection period was defined as the time from SARS-CoV-2 diagnosis (by BinaxNOW™ COVID-

314 19 Ag Cards and/or real-time reverse transcription polymerase chain reaction) to receipt of first Pfizer-

BioNTech COVID-19 Vaccine dose. The post-vaccination period was defined as the time after receipt of

316 first vaccine dose to the end of the evaluation period.

⁺ Individuals with serum antibody titers below the seroconversion threshold (defined as a signal

318 threshold >1 at the 1:100 dilution for any isotype) were not included in geometric mean and ratio

- 319 calculations. Geometric means of IgM titers and ratios were not calculated during 61–90 days because
- 320 all post-vaccination titers were below the limit of detection. Participant G was not included in the post-
- 321 infection analyses because they did not provide blood specimens during this time period. Participant C
- 322 was not included in the post-vaccination analyses due to vaccination refusal. This participant's titers
- 323 ranged from 2437–16977 for Pan-Ig, 4919–7045 for IgG, and 267–710 for IgA during the 90–150 days
- 324 post-infection; their IgM titers were below the limit of detection during this time period.

325 Figure 1. Timeline of participant visits and evaluation activities conducted, by time period—Georgia,



326 October 2020–April 2021

Upon enrollment after a SARS-CoV-2–positive diagnosis by BinaxNOW™ COVID-19 Ag Cards and/or real-328 329 time reverse transcription polymerase chain reaction, the first four visits were conducted every other 330 day. Visits 5–9 occurred monthly. The post-diagnosis period was defined as the time after each 331 participant's first positive SARS-CoV-2 test result. The post-infection period was defined as the time 332 from SARS-CoV-2 diagnosis to receipt of first Pfizer-BioNTech COVID-19 Vaccine dose. The post-333 vaccination period was defined as the time after receipt of first vaccine dose to the end of the 334 evaluation period. Nine participants received their two vaccine doses 21 days apart; one participant 335 received their two vaccine doses 28 days apart.

Figure 2. Distribution of anti–SARS-CoV-2 serum antibody titers by isotype and time period among

337 participants (N=11) in a nursing home cohort—Georgia, October 2020–April 2021



340 The post-infection period was defined as the time from SARS-CoV-2 diagnosis (by BinaxNOW™ COVID-19 341 Ag Cards and/or real-time reverse transcription polymerase chain reaction) to receipt of first Pfizer-342 BioNTech COVID-19 Vaccine dose. The post-vaccination period was defined as the time after receipt of 343 first vaccine dose to the end of the evaluation period. Participant G was not included in the post-344 infection analyses because they did not provide blood specimens during this time period. Participant C 345 was not included in the post-vaccination analyses due to vaccination refusal. Participants with serum antibody titers below the seroconversion threshold (defined as a signal threshold >1 at the 1:100 346 347 dilution for any isotype) were assigned a value of 25 for graphical representation only. In each box and 348 whisker plot, the horizontal line represents the median, and the top and bottom of the box the 349 interquartile range, and the whiskers the minimum and maximum values. The y-axis is plotted in 350 logarithmic scale. Only three observations were above the limit of detection during 0–14 days post-351 vaccination for IgM and IgA; IgM titers during this time period ranged from 313–3013 and IgA titers 352 ranged from 177–890.

354 **References:**

355	1.	Centers for Medicare & Medicaid Services. COVID-19 nursing home data. 2021. Accessed at
356		https://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg on 17 December
357		2021.
358	2.	White EM, Saade EA, Yang X, et al. SARS-CoV-2 antibody detection in skilled nursing facility
359		residents. J Am Geriatr Soc. 2021;69(7):1722-1728. [PMID: 33544876] doi:10.1111/jgs.17061.
360	3.	Dora AV, Winnett A, Fulcher JA, et al. Using Serologic Testing to Assess the Effectiveness of
361		Outbreak Control Efforts, Serial PCR Testing, and Cohorting of Positive SARS-CoV-2 Patients in a
362		Skilled Nursing Facility. Clin Infect Dis. 2021;73(3):545-548. [PMID: 32857830]
363		doi:10.1093/cid/ciaa1286.
364	4.	CDC. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or
365		Authorized in the United States. Updated 17 December 2021. Accessed at
366		https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html on 20
367		December 2021.
368	5.	Mor V, Gutman R, Yang X, et al. Short-term impact of nursing home SARS-CoV-2 vaccinations on
369		new infections, hospitalizations, and deaths. J Am Geriatr Soc. 2021;69(8):2063-2069. [PMID:
370		33861873] doi:10.1111/jgs.17176.
371	6.	U.S. Food and Drug Administration. Vaccines and Related Biological Products Advisory
372		Committee Meeting. 10 December 2020. Accessed at
373		https://www.fda.gov/media/144245/download on 11 April 2021.
374	7.	Dooling K, McClung N, Chamberland M, et al. The Advisory Committee on Immunization
375		Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United
376		States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(49):1857-1859. [PMID: 33301429]
377		doi:10.15585/mmwr.mm6949e1.
378	8.	Cavanaugh AM, Fortier S, Lewis P, et al. COVID-19 Outbreak Associated with a SARS-CoV-2 R.1
379		Lineage Variant in a Skilled Nursing Facility After Vaccination Program — Kentucky, March 2021.
380		MMWR Morb Mortal Wkly Rep. 2021;70(17):639-643. [PMID: 33914720] doi:
381		10.15585/mmwr.mm7017e2.
382	9.	Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in
383		Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During
384		Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare
385		Safety Network, March 1–August 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163-
386		1166. [PMID: 34437519] doi: 10.15585/mmwr.mm7034e3.
387	10.	Emborg H-D, Valentiner-Branth P, Schelde AB, et al. Vaccine effectiveness of the BNT162b2
388		mRNA COVID-19 vaccine against RT-PCR confirmed SARS-CoV-2 infections, hospitalisations and
389		mortality in prioritised risk groups. medRxiv [Preprint]. 2021 [cited 20 September 2021].
390		Available from: https://www.medrxiv.org/content/10.1101/2021.05.27.21257583v1.
391	11.	Mazagatos C, Monge S, Olmedo C, et al. Effectiveness of mRNA COVID-19 vaccines in preventing
392		SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care
393		facility residents, Spain, weeks 53 2020 to 13 2021. Euro Surveill. 2021;26(24):2100452. [PMID:
394		34142647] doi: 10.2807/1560-7917.ES.2021.26.24.2100452.
395	12.	McKay SL, Tobolowsky FA, Moritz ED, et al. Performance Evaluation of Serial SARS-CoV-2 Rapid
396		Antigen Testing During a Nursing Home Outbreak. Ann Intern Med. 2021;174(7):945-951.
397		[PMID: 33900791] doi: 10.7326/M21-0422.
398	13.	Moritz ED, McKay SL, Tobolowsky FA, et al. Repeated Antigen Testing Among SARS-CoV-2-
399		Positive Nursing Home Residents. Infect Control Hosp Epidemiol. 2021;1-10. [PMID: 34412728]
400		doi:10.1017/ice.2021.370.

401	14.	U.S. Food and Drug Administration. In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for
402		SARS-CoV-2. Updated 15 September 2021. Accessed at: <u>https://www.fda.gov/medical-</u>
403		devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-
404		vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular on 20
405		September 2021.
406	15.	Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international
407		community of software platform partners. J Biomed Inform. 2019;95:103208. [PMID: 31078660]
408		doi:10.1016/j.jbi.2019.103208.
409	16.	Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)a metadata-
410		driven methodology and workflow process for providing translational research informatics
411		support. J Biomed Inform. 2009;42(2):377-381. [PMID: 18929686] doi:10.1016/j.jbi.2008.08.010.
412	17.	CDC. Discontinuation of Transmission-Based Precautions and Disposition of Patients with SARS-
413		CoV-2 Infection in Healthcare Settings. Updated 10 September 2021. Accessed at:
414		https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html on 20
415		December 2021.
416	18.	Freeman B, Lester S, Mills L, et al. Validation of a SARS-CoV-2 spike protein ELISA for use in
417		contact investigations and serosurveillance. bioRxiv [Preprint]. 2020:2020.04.24.057323. [PMID:
418		32511332] doi: 10.1101/2020.04.24.057323.
419	19.	Protection of Human Subjects. 45 C.F.R. part 46.102(1)(1) (2018).
420	20.	Institutional Review Boards. 21 C.F.R. part 56 (1981).
421	21.	Records Maintained on Individuals. 5 U.S.C. §552a (2018).
422	22.	Purposes. 44 U.S.C. §3501 (2018).
423	23.	Research and Investigations Generally, 42 U.S.C. §241(d) (2011).
424	24.	Harvey RA, Rassen JA, Kabelac CA, et al. Association of SARS-CoV-2 Seropositive Antibody Test
425		With Risk of Future Infection. JAMA Intern Med. 2021;181(5):672-679. [PMID: 33625463]
426		doi:10.1001/iamainternmed.2021.0366.
427	25.	Glans H. Gredmark-Russ S. Olausson M. et al. Shedding of infectious SARS-CoV-2 by hospitalized
428	-	COVID-19 patients in relation to serum antibody responses. BMC Infect Dis. 2021:21(1):494.
429		[PMID: 34044758] doi:10.1186/s12879-021-06202-8.
430	26.	Surie D, Huang JY, Brown AC, et al. Infectious Period of Severe Acute Respiratory Syndrome
431		Coronavirus 2 in 17 Nursing Home Residents-Arkansas, June-August 2020. Open Forum Infect
432		Dis. 2021:8(3):ofab048. [PMID: 33723510] doi:10.1093/ofid/ofab048.
433	27.	Wu LX. Wang H. Gou D. et al. Clinical significance of the serum IgM and IgG to SARS-CoV-2 in
434		coronavirus disease-2019. J Clin Lab Anal. 2021:35(1):e23649. [PMID: 33184940]
435		doi:10.1002/icla.23649.
436	28.	Shu H. Wang S. Ruan S. et al. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19
437	-	Patients at Early Stage of Outbreak, Virol Sin, 2020:35(6):744-751, [PMID: 32720214]
438		doi:10.1007/s12250-020-00268-5.
439	29.	Staines HM, Kirwan DE, Clark DJ, et al. IgG Seroconversion and Pathophysiology in Severe Acute
440		Respiratory Syndrome Coronavirus 2 Infection. Emerg Infect Dis. 2021;27(1):85-91. [PMID:
441		33256890] doi:10.3201/eid2701.203074.
442	30	Eu Y. Pan Y. Li Z. et al. The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory
443	20.	Diagnosis, Front Microbiol, 2021:11:603058, [PMID: 33519745] doi:10.3389/fmicb.2020.603058
444	31	Hasan Ali O. Bomze D. Risch L. et al. Severe COVID-19 is associated with elevated serum IgA and
445	<u> </u>	antiphospholipid IgA-antibodies. Clin Infect Dis. 2021;73(9):1746. [PMID: 34550333]
446		doi:10.1093/cid/ciab532.
-		, ,

447	32.	Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8
448		months after infection. Science. 2021;371(6529):eabf4063. [PMID: 33408181]
449		doi:10.1126/science.abf4063.
450	33.	Ruopp MD, Strymish J, Dryjowicz-Burek J, et al. Durability of SARS-CoV-2 lgG Antibody Among
451		Residents in a Long-Term Care Community. J Am Med Dir Assoc. 2021;22(3):510-511. [PMID:
452		33515497] doi:10.1016/j.jamda.2021.01.066.
453	34	Widge AT, Rouphael NG, Jackson LA, et al. Durability of Responses after SARS-CoV-2 mRNA-1273
454		Vaccination. N Engl J Med. 2021;384(1):80-82. [PMID: 33270381] doi:10.1056/NEJMc2032195.
455	35	Bradley T, Grundberg E, Selvarangan R, et al. Antibody Responses after a Single Dose of SARS-
456		CoV-2 mRNA Vaccine. N Engl J Med. 2021;384(20):1959-1961. [PMID: 33755375]
457		doi:10.1056/NEJMc2102051.
458	36	Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously
459		SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057-1058. [PMID: 33640038]
460		doi:10.1016/S0140-6736(21)00501-8.
461	37.	Gobbi F, Buonfrate D, Moro L, et al. Antibody Response to the BNT162b2 mRNA COVID-19
462		Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses. 2021;13(3):422. [PMID: 33807957]
463		doi:10.3390/v13030422.
464	38	Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
465		asymptomatic SARS-CoV-2 infection. Nat Med. 2021;10.1038/s41591-021-01540-1. [PMID:
466		34588689] doi:10.1038/s41591-021-01540-1.
467	39.	Wisnewski AV, Campillo Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA
468		vaccines. PLoS One. 2021;16(6):e0249499. [PMID: 34133415]
469		doi:10.1371/journal.pone.0249499.
470	40	Ketas TJ, Chaturbhuj D, Cruz-Portillo VM, et al. Antibody responses to SARS-CoV-2 mRNA
471		vaccines are detectable in saliva. Pathog Immun. 2021;6(1):116-134. [PMID: 34136730]
472		doi:10.20411/pai.v6i1.441.
473	41	Danese E, Montagnana M, Salvagno GL, et al. Comprehensive assessment of humoral response
474		after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series. Clin Chem Lab Med.
475		2021;59(9):1585-1591. [PMID: 33838087] doi:10.1515/cclm-2021-0339.
476	42	Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to
477		SARS-CoV-2. Sci Transl Med. 2021;13(577):eabd2223. [PMID: 33288662]
478		doi:10.1126/scitranslmed.abd2223.
479	43	Unroe KT, Evans R, Weaver L, et al. Willingness of Long-Term Care Staff to Receive a COVID-19
480		Vaccine: A Single State Survey. J Am Geriatr Soc. 2021;69(3):593-599. [PMID: 33370448]
481		doi:10.1111/jgs.17022.